Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Biohaven Ltd. (NYSE: BHVN) presented data on its novel compound BHV-7000 at the ASENT 2023 Annual Meeting, focusing on its efficacy and safety in treating epilepsy. BHV-7000, a Kv7.2/7.3 potassium channel activator, shows potent anti-seizure capabilities without negatively impacting neurobehavior. The Phase 1 trial indicated good tolerability at doses up to 100 mg, with no severe adverse events observed. Leading researchers emphasized the potential for BHV-7000 to deliver efficacy without common CNS-related side effects seen in existing anti-seizure medications, marking a significant advancement in epilepsy treatment.
- BHV-7000 demonstrates potent anti-seizure activity without adverse neurobehavioral effects.
- Phase 1 trial shows BHV-7000 is well-tolerated, with no serious adverse events.
- CNS side effect profile of BHV-7000 is favorable compared to current anti-seizure medications.
- None.
- BHV-7000 differs pharmacologically and structurally from other known Kv7 compounds in development
- BHV-7000 demonstrates potent anti-seizure activity without effects on neurobehavior in preclinical models
- BHV-7000 CNS side effect profile in Phase 1 compares favorably to anti-seizure medications currently approved and in clinical development
The presentation slides and an accompanying posters will be available on the Events and Presentations page of the Investors section of
About
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the Food and Drug Administration; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Biohaven Contacts:
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741
mikebeyer@sambrown.com
312-961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-announces-presentation-at-the-american-society-for-experimental-neurotherapeutics-asent-annual-meeting-301770599.html
SOURCE
FAQ
What is BHV-7000 and its significance in epilepsy treatment?
What were the results of the Phase 1 trial for BHV-7000?
When and where was BHV-7000 presented?
What company is developing BHV-7000?